Search Results - "Heigener, D"

Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients by Kuempers, C., van der Linde, L. I. S., Reischl, M., Vogel, W., Stellmacher, F., Reck, M., Heigener, D., Rabe, K. F., Kirfel, J., Perner, S., Welker, L.

“…Expression of programmed death ligand 1 assessed on histologic samples is a confirmed predictive biomarker for anti-PD-1 immunotherapy, but its evaluation is…”
Get full text

Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade by Braeken, D. C. W., Essig, A., Panning, M., Hoerster, R., Nawrocki, M., Dalhoff, K., Suttorp, N., Welte, T., Pletz, M. W., Witzenrath, M., Rohde, G. G. U., Rupp, J.

“…To determine the most relevant pathogens for CAP in Germany, patients with radiologically confirmed pulmonary infiltrates and at least one clinical sign of…”
Get full text

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer by Heigener, D.F, Deppermann, K.M, Pawel, J.v, Fischer, J.R, Kortsik, C, Bohnet, S, Eiff, M.v, Koester, W, Thomas, M, Schnabel, P.A, Reck, M

“…Abstract Background Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less…”
Get full text

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial by Bozorgmehr, F., Hommertgen, A., Lasitschka, F., Krisam, J., Debus, J., Fischer, J.R., Bischof, M., Atmaca, A., Wetzel, S., Faehling, M., Bottke, D., Grohe, C., Engel-Riedel, W., Ingenhoff, E., Heigener, D.F., Reinmuth, N., Schumann, C., Wermke, M., Thomas, M., Rieken, S.

Get full text

No SARS-CoV-2 detection in the German CAPNETZ cohort of community acquired pneumonia before COVID-19 peak in March 2020 by Panning, Marcus, Wiener, Julius, Rothe, Kathrin, Schneider, Jochen, Pletz, Mathias W., Rohde, Gernot, Rupp, Jan, Witzenrath, Martin, Spinner, Christoph D.

“…Purpose The first SARS-CoV-2 cases in Europe were reported in January 2020. Recently, concern arose on unrecognized infections before this date. For a better…”
Get full text

3102 Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: Analysis of data from the LUME-Lung 1 study by Reck, M, Buchner, H, Gottfried, M, Novello, S, Mellemgaard, A, Heigener, D, Gaschler-Markefski, B, Kaiser, R, Douillard, J.Y

Get full text

Palliative care concepts in respiratory disease by Heigener, D F, Rabe, K F

“…Many respiratory diseases besides lung cancer are still not curable. There is an unmet need for palliative care, especially in non-malignant conditions. In…”
Get more information

Rebiopsy for Patients with Lung Cancer - Joint Opinion from both the Endoscopic and Thoracic Oncology Sections of the German Society of Pneumology (DGP) by Brückl, W M, Ficker, J H, Tiemann, M, Schumann, C, Reinmuth, N, Heigener, D, Schütte, W, Eberhardt, R, Darwiche, K, Wagner, M

“…Performing rebiopsies for primary lung cancer and/or their metastases is becoming more and more prominent in daily practice, as the therapeutical spectrum…”
Get more information

Chemotherapy of malignant pleural mesothelioma: have we made any progress? by Reck, M, Heigener, D F, Gatzemeier, U

“…Chemotherapy of malignant mesothelioma is of great importance because most patients with malignant pleural mesothelioma are diagnosed for the first time with…”
Get more information

Palliativmedizinische Aspekte beim kleinzelligen Lungenkarzinom by Sebastian, M., Heigener, D., Alt-Epping, B.

“…Zusammenfassung Hintergrund Das kleinzellige Lungenkarzinom (SCLC) ist ein aggressiv wachsender Tumor mit ungünstiger Prognose. Bislang existieren wenige Daten…”
Get full text

Targeted therapy and precision medicine : More than just words in the treatment of lung cancer by Heigener, D F, Horn, M, Reck, M

“…Between 10 and 15 % of non-small cell lung cancers (NSCLC) proliferate due to the presence of a so-called driver mutation. This molecular alteration allows the…”
Get full text

9146 Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response by Schumann, C, Heigener, D, Dittrich, I, Abenhardt, W, Dederke, B, Duell, T, Matzdorff, A, Raack, B.W, Steins, M, Schneider, C.P

Get full text

Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries by Linschoten, M, Uijl, A, Schut, A, Jakob, C E M, Romão, L R, Bell, R M, McFarlane, E, Stecher, M, Zondag, A G M, van Iperen, E P A, Hermans-van Ast, W, Lea, N C, Schaap, J, Jewbali, L S, Smits, P C, Patel, R S, Aujayeb, A, van der Harst, P, Siebelink, H J, van Smeden, M, Williams, S, Pilgram, L, van Gilst, W H, Tieleman, R G, Williams, B, Asselbergs, F W, Al-Ali, A K, Al-Muhanna, F A, Al-Rubaish, A M, Al-Windy, N Y Y, Alkhalil, M, Almubarak, Y A, Alnafie, A N, Alshahrani, M, Alshehri, A M, Anning, C, Anthonio, R L, Badings, E A, Ball, C, van Beek, E A, ten Berg, J M, von Bergwelt-Baildon, M, Bianco, M, Blagova, O V, Bleijendaal, H, Bor, W L, Borgmann, S, van Boxem, A J M, van den Brink, F S, Bucciarelli-Ducci, C, van Bussel, B C T, Byrom-Goulthorp, R, Captur, G, Caputo, M, Charlotte, N, vom Dahl, J, Dark, P, De Sutter, J, Degenhardt, C, Delsing, C E, Dolff, S, Dorman, H G R, Drost, J T, Eberwein, L, Emans, M E, Er, A G, Ferreira, J B, Forner, M J, Friedrichs, A, Gabriel, L, Groenemeijer, B E, Groenendijk, A L, Grüner, B, Guggemos, W, Haerkens-Arends, H E, Hanses, F, Hedayat, B, Heigener, D, van der Heijden, D J, Hellou, E, Hellwig, K, Henkens, M T H M, Hermanides, R S, Hermans, W R M, van Hessen, M W J, Heymans, S R B, Hilt, A D, van der Horst, I C C, Hower, M, van Ierssel, S H, Isberner, N, Jensen, B, Kearney, M T, van Kesteren, H A M, Kielstein, J T, Kietselaer, B L J H, Kochanek, M, Kolk, M Z H, Koning, A M H, Kopylov, P Y

“…Abstract Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study…”
Get full text

Lung cancer : What has been confirmed in therapy? by Heigener, D F, Reck, M

“…Metastatic non-small cell lung cancer has now been subdivided into several subtypes. The five basic principles of treatment include chemotherapy,…”
Get full text

Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)—A prospective multicenter study by Dähne, Theo, Bauer, Wolfgang, Essig, Andreas, Schaaf, Bernhard, Barten-Neiner, Grit, Spinner, Christoph D., Pletz, Mathias W., Rohde, Gernot, Rupp, Jan, Witzenrath, Martin, Panning, Marcus, Fuchs, A., Engelmannn, M., Stolz, D., Bauer, W., Mücke, H.C., Suttorp, N., Witzenrath, M., Schmager, S., Schaaf, B., Kremling, J., Nickoleit-Bitzenberger, D., Azzaui, H., Hower, M., Hempel, F., Prebeg, K., Popkirova, K., Kolditz, M., Rohde, G., Bellinghausen, C., Grünewaldt, A., Panning, M., Welte, T., Fühner, T., van't Klooster, M., Barten-Neiner, G., Kröner, W., Unruh, Ol, Adaskina, N., Eberherdt, F., Julius, C., Illig, T., Klopp, N., Pletz, M., Schleenvoigt, B.T., Forstner, C., Moeser, A., Ankert, J., Drömannn, D., Parschke, P., Franzen, K., Rupp, J., Käding, N., Waldeck, F., Spinner, C., Erber, J., Voit, F., Schneider, J., Heigener, D., Hering, I., Albrich, W., Seneghini, M., Rassouli, F., Baldesberger, S., Essig, A., Stenger, S., Wallner, M., Burgmann, H., Traby, L., Schubert, L., Chen, R.

“…•Community-acquired pneumonia (CAP) in adults is a major public health concern.•Respiratory viruses are increasingly recognized as an important cause of…”
Get full text

Comparison of clinical outcomes in hospitalized patients with COVID-19 or non-COVID-19 community-acquired pneumonia in a prospective observational cohort study by Meyer, Hans-Jakob, Mödl, Lukas, Unruh, Olesya, Xiang, Weiwei, Berger, Sarah, Müller-Plathe, Moritz, Rohde, Gernot, Pletz, Mathias W, Rupp, Jan, Suttorp, Norbert, Witzenrath, Martin, Zoller, Thomas, Mittermaier, Mirja, Steinbeis, Fridolin

“…Coronavirus disease 2019 (COVID-19) and non-COVID-19 community-acquired pneumonia (NC-CAP) often result in hospitalization with considerable risks of…”
Get full text

Was sollte der Pneumologe über Palliativmedizin wissen? by Nehls, W., Heigener, D. F.

“…Zusammenfassung Palliativmedizin ist mit dem Fachgebiet der Pneumologie untrennbar verbunden, da hier viele unheilbare Erkrankungen mit eingeschränkter…”
Get full text

Treatment of non-small cell lung cancer by Reinmuth, N, Heigener, D, Reck, M

“…Within recent years, the treatment of non-small cell lung cancer has become increasingly heterogeneous and complex. New cytotoxic agents and drugs against…”
Get full text

Molecular Profiling of Non-Small Cell Lung Cancer with Cytologic Specimens in the Absence of Histologic Specimens by Heigener, D., Falk, M., Kanappilly, A., Tiemann, M., Reck, M., Welker, L.

Get full text

188PMOLECULAR PROFILING OF NON-SMALL CELL LUNG CANCER WITH CYTOLOGIC SPECIMENS IN THE ABSENCE OF HISTOLOGIC SPECIMENS by Heigener, D., Falk, M., Kanappilly, A., Tiemann, M., Reck, M., Welker, L.

“…Abstract Aim: Non-Small Cell Lung Cancer (NSCLC) harbours different mutations and gene-rearrangements which should be tested because of predictive or…”
Get full text